alpha-aminopyridine has been researched along with Experimental Mammary Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bona, BJ; Moyer, ML; Nordeen, SK | 1 |
| Chen, F; Li, T; Wang, Q; Wang, Y; Xiong, Y; Yu, X; Zeng, Y; Zhou, F; Zhou, Y | 1 |
| Allen, RJ; Bishop, RT; de Ridder, D; Idris, AI; Lefley, DV; Marino, S; Ottewell, PD; Sims, AH; Wang, N | 1 |
| Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L | 1 |
4 other study(ies) available for alpha-aminopyridine and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Modulation of glucocorticoid-regulated transcription by purines: novel characteristics and implications for tissue specificity of steroid responses.
Topics: 1-Methyl-3-isobutylxanthine; Aminopyridines; Animals; Carcinoma; Gene Expression Regulation; Glucocorticoids; Kinetics; Mammary Neoplasms, Experimental; Mice; Purines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Topics: Aminopyridines; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor Proteins; E2F1 Transcription Factor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Phosphorylation; Purines; Retinoblastoma Protein; Triple Negative Breast Neoplasms; Tumor Burden | 2019 |
Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; I-kappa B Kinase; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RAW 264.7 Cells | 2019 |
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |